Skip to main content
Erschienen in: Journal of Clinical Immunology 5/2007

01.09.2007

Primary Immunodeficiency Diseases in Australia and New Zealand

verfasst von: Philippa Kirkpatrick, Sean Riminton

Erschienen in: Journal of Clinical Immunology | Ausgabe 5/2007

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Despite rapid developments in the science of primary immunodeficiency diseases (PID), population characteristics and the burden of disease are poorly characterized. Aggregated data on PID via patient registries are a key component of the public health response. The web-enabled Australasian Society of Clinical Immunology and Allergy PID Register was designed and implemented to address gaps in knowledge of PID.

Methods

The register provided a cumulative, cross-sectional survey of PID patients in Australia and New Zealand via an online, single time point, center-based, voluntarily recalled, and patient-consented questionnaire.

Result

Eighty-eight centers reported 1,209 patients across 56 separate PID syndromes. The study prevalence (cases per 100,000 population) was 5.6 for Australia, 12.4 for the state of South Australia, and 4.9 for Australia and New Zealand combined. Predominately antibody deficiency syndromes accounted for 77% of patients. Common variable immunodeficiency was the most common diagnosis. Patients were geographically dispersed with 80% of centers reporting caseloads of less than 20 patients. Potentially preventable complications of disease were common. Immunoglobulin replacement therapy was used in 30 conditions with 26.5% of the total recipients having antibody deficiency disorders with normal serum IgG.

Conclusion

PID in Australia and New Zealand are prevalent, clinically diverse, geographically dispersed, and are characterized by high rates of potentially preventable morbidity and resource utilization. A public health focus on PID is required, including strategies to correct disparities in access to care, improve molecular diagnostics and reduce preventable complications of disease. Further studies in antibody deficiency syndromes with normal serum IgG are required.
Literatur
1.
Zurück zum Zitat Lindegren ML, Kobrynski L, Rasmussen SA, Moore CA, Grosse SD, Vanderford ML, et al. Applying public health strategies to primary immunodeficiency diseases: a potential approach to genetic disorders. Morb Mortal Wkly Rep 2004;53:1–29. Lindegren ML, Kobrynski L, Rasmussen SA, Moore CA, Grosse SD, Vanderford ML, et al. Applying public health strategies to primary immunodeficiency diseases: a potential approach to genetic disorders. Morb Mortal Wkly Rep 2004;53:1–29.
2.
Zurück zum Zitat European Commission. Consensus report and recommendations. in: Proceedings of the European Primary Immunodeficiencies Consensus Conference, Langen, Germany; 2006. European Commission. Consensus report and recommendations. in: Proceedings of the European Primary Immunodeficiencies Consensus Conference, Langen, Germany; 2006.
3.
Zurück zum Zitat Notarangelo L, Casanova JL, Conley ME, Chapel H, Fischer A, Puck J, et al. Primary immunodeficiency diseases: an update. J Allergy Clin Immunol 2006;117:883–96.PubMedCrossRef Notarangelo L, Casanova JL, Conley ME, Chapel H, Fischer A, Puck J, et al. Primary immunodeficiency diseases: an update. J Allergy Clin Immunol 2006;117:883–96.PubMedCrossRef
4.
Zurück zum Zitat Baumgart KW, Britton WJ, Kemp A, French M, Roberton D. The spectrum of primary immunodeficiency disorders in Australia. J Allergy Clin Immunol 1997;100:415–23.PubMedCrossRef Baumgart KW, Britton WJ, Kemp A, French M, Roberton D. The spectrum of primary immunodeficiency disorders in Australia. J Allergy Clin Immunol 1997;100:415–23.PubMedCrossRef
5.
Zurück zum Zitat Australian Bureau of Statistics. Australian Demographic Statistics: 3101.0; June 2006. Australian Bureau of Statistics. Australian Demographic Statistics: 3101.0; June 2006.
6.
Zurück zum Zitat Statistics New Zealand. National Population Estimates; June 2006. Statistics New Zealand. National Population Estimates; June 2006.
7.
Zurück zum Zitat Aittoniemi J, Koskinen S, Laippala P, Laine S, Miettinen A. The significance of IgG subclass deficiency and mannan-binding lectin (MBL) for susceptibility to infection in apparently healthy adults with IgA deficiency. Clin Exp Immunol 1999;116:505–8.PubMedCrossRef Aittoniemi J, Koskinen S, Laippala P, Laine S, Miettinen A. The significance of IgG subclass deficiency and mannan-binding lectin (MBL) for susceptibility to infection in apparently healthy adults with IgA deficiency. Clin Exp Immunol 1999;116:505–8.PubMedCrossRef
8.
Zurück zum Zitat Bonilla FA, Bernstein IL, Khan DA, Ballas ZK, Chinen J, Frank MM, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 2005;94:S1–63.PubMedCrossRef Bonilla FA, Bernstein IL, Khan DA, Ballas ZK, Chinen J, Frank MM, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 2005;94:S1–63.PubMedCrossRef
9.
Zurück zum Zitat Cunningham-Rundles C, Ponda PP. Molecular defects in T- and B-cell primary immunodeficiency diseases. Nat Rev Immunol 2005;5:880–92.PubMedCrossRef Cunningham-Rundles C, Ponda PP. Molecular defects in T- and B-cell primary immunodeficiency diseases. Nat Rev Immunol 2005;5:880–92.PubMedCrossRef
10.
Zurück zum Zitat Australasian Society of Clinical Immunology and Allergy. Clinical Immunology and Allergy Workforce Survey; 2007. Australasian Society of Clinical Immunology and Allergy. Clinical Immunology and Allergy Workforce Survey; 2007.
11.
Zurück zum Zitat Roche P. Tuberculosis notifications in Australia, 2004. Commun Dis Intell 2006;30:93–101.PubMed Roche P. Tuberculosis notifications in Australia, 2004. Commun Dis Intell 2006;30:93–101.PubMed
12.
Zurück zum Zitat Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006;117:S525–53.PubMedCrossRef Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006;117:S525–53.PubMedCrossRef
13.
Zurück zum Zitat Buckley RH. Immunoglobulin G subclass deficiency: fact or fancy? Curr Allergy Asthma Rep 2002;2:356–60.PubMedCrossRef Buckley RH. Immunoglobulin G subclass deficiency: fact or fancy? Curr Allergy Asthma Rep 2002;2:356–60.PubMedCrossRef
14.
Zurück zum Zitat Casanova JL, Fieschi C, Bustamante J, Reichenbach J, Remus N, von Bernuth H, et al. From idiopathic infectious diseases to novel primary immunodeficiencies. J Allergy Clin Immunol 2005;116:426–30.PubMedCrossRef Casanova JL, Fieschi C, Bustamante J, Reichenbach J, Remus N, von Bernuth H, et al. From idiopathic infectious diseases to novel primary immunodeficiencies. J Allergy Clin Immunol 2005;116:426–30.PubMedCrossRef
15.
Zurück zum Zitat Stray-Pedersen A, Abrahamsen TG, Froland SS. Primary immunodeficiency diseases in Norway. J Clin Immunol 2000;20: 477–85.PubMedCrossRef Stray-Pedersen A, Abrahamsen TG, Froland SS. Primary immunodeficiency diseases in Norway. J Clin Immunol 2000;20: 477–85.PubMedCrossRef
16.
Zurück zum Zitat Llambi MJ, Etxagibel Galdos A, Matamoros N. The Spanish Registry of Primary Immunodeficiencies (REDIP). Allergol Immunopathol (Madr) 2001;29:122–5. Llambi MJ, Etxagibel Galdos A, Matamoros N. The Spanish Registry of Primary Immunodeficiencies (REDIP). Allergol Immunopathol (Madr) 2001;29:122–5.
17.
Zurück zum Zitat Abuzakouk M, Feighery C. Primary immunodeficiency disorders in the Republic of Ireland: first report of the national registry in children and adults. J Clin Immunol 2005;25:73–7.PubMedCrossRef Abuzakouk M, Feighery C. Primary immunodeficiency disorders in the Republic of Ireland: first report of the national registry in children and adults. J Clin Immunol 2005;25:73–7.PubMedCrossRef
18.
Zurück zum Zitat Costabile M, Quach A, Ferrante A. Molecular approaches in the diagnosis of primary immunodeficiency diseases. Hum Mutat 2006;27:1163–73.PubMedCrossRef Costabile M, Quach A, Ferrante A. Molecular approaches in the diagnosis of primary immunodeficiency diseases. Hum Mutat 2006;27:1163–73.PubMedCrossRef
19.
Zurück zum Zitat Thickett KM, Kumararatne DS, Banerjee AK, Dudley R, Stableforth DE. Common variable immune deficiency: respiratory manifestations, pulmonary function and high-resolution CT scan findings. Q J Med 2002;95:655–62. Thickett KM, Kumararatne DS, Banerjee AK, Dudley R, Stableforth DE. Common variable immune deficiency: respiratory manifestations, pulmonary function and high-resolution CT scan findings. Q J Med 2002;95:655–62.
20.
Zurück zum Zitat Seymour B, Miles J, Haeney M. Primary antibody deficiency and diagnostic delay. J Clin Pathol 2005;58:546–7.PubMedCrossRef Seymour B, Miles J, Haeney M. Primary antibody deficiency and diagnostic delay. J Clin Pathol 2005;58:546–7.PubMedCrossRef
21.
Zurück zum Zitat De Gracia J, Vendrell M, Alvarez A, Pallisa E, Rodrigo MJ, de la Rosa D, et al. Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency. Int Immunopharmacol 2004;4:745–53.PubMedCrossRef De Gracia J, Vendrell M, Alvarez A, Pallisa E, Rodrigo MJ, de la Rosa D, et al. Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency. Int Immunopharmacol 2004;4:745–53.PubMedCrossRef
22.
Zurück zum Zitat Vendrell M, de Gracia J, Rodrigo MJ, Cruz MJ, Alvarez A, Garcia M, et al. Antibody production deficiency with normal IgG levels in bronchiectasis of unknown aetiology. Chest 2005;127:197–204.PubMedCrossRef Vendrell M, de Gracia J, Rodrigo MJ, Cruz MJ, Alvarez A, Garcia M, et al. Antibody production deficiency with normal IgG levels in bronchiectasis of unknown aetiology. Chest 2005;127:197–204.PubMedCrossRef
Metadaten
Titel
Primary Immunodeficiency Diseases in Australia and New Zealand
verfasst von
Philippa Kirkpatrick
Sean Riminton
Publikationsdatum
01.09.2007
Verlag
Springer US
Erschienen in
Journal of Clinical Immunology / Ausgabe 5/2007
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-007-9105-z

Weitere Artikel der Ausgabe 5/2007

Journal of Clinical Immunology 5/2007 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.